These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1154 related items for PubMed ID: 27118127

  • 1. Prognostic impact of incomplete surgical clearance of radioiodine sensitive local lymph node metastases diagnosed by post-operative (124)I-NaI-PET/CT in patients with papillary thyroid cancer.
    Sabet A, Binse I, Grafe H, Ezziddin S, Görges R, Poeppel TD, Bockisch A, Rosenbaum-Krumme SJ.
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1988-94. PubMed ID: 27118127
    [Abstract] [Full Text] [Related]

  • 2. PROGNOSTIC VALUE OF LYMPH NODE UPTAKE ON PRETREATMENT F-18 FDG PET/CT IN PATIENTS WITH N1B PAPILLARY THYROID CARCINOMA.
    Lee CH, Lee SW, Son SH, Hong CM, Jeong JH, Jeong SY, Ahn BC, Lee J.
    Endocr Pract; 2019 Aug; 25(8):787-793. PubMed ID: 31013158
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
    Wu MH, Shen WT, Gosnell J, Duh QY.
    Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
    [Abstract] [Full Text] [Related]

  • 4. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH, Jung DW, Pak KJ, Kim IJ, Kim HJ, Cho JK, Shin SC, Wang SG, Lee BJ.
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [Abstract] [Full Text] [Related]

  • 5. Location and Causation of Residual Lymph Node Metastasis After Surgical Treatment of Regionally Advanced Differentiated Thyroid Cancer.
    Miller JE, Al-Attar NC, Brown OH, Shaughness GG, Rosculet NP, Avram AM, Hughes DT.
    Thyroid; 2018 May; 28(5):593-600. PubMed ID: 29562827
    [Abstract] [Full Text] [Related]

  • 6. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC.
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [Abstract] [Full Text] [Related]

  • 7. [Value of (18)F-FDG dual head coincidence imaging in predicting the efficacy of radioiodine therapy for papillary thyroid carcinoma with cervical lymph node metastasis].
    Sun YG, Feng HJ, Liu JH, Hu R, Ouyang W.
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Sep; 31(9):1571-4. PubMed ID: 21945769
    [Abstract] [Full Text] [Related]

  • 8. Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma.
    Sabet A, Binse I, Dogan S, Koch A, Rosenbaum-Krumme SJ, Biersack HJ, Biermann K, Ezziddin S.
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):190-195. PubMed ID: 27530124
    [Abstract] [Full Text] [Related]

  • 9. Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma.
    Kim SK, So Y, Chung HW, Yoo YB, Park KS, Hwang TS, Kim B, Lee WW.
    Cancer Med; 2016 Oct; 5(10):2756-2762. PubMed ID: 27539659
    [Abstract] [Full Text] [Related]

  • 10. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
    Weber T, Ohlhauser D, Hillenbrand A, Henne-Bruns D, Reske SN, Luster M.
    Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
    [Abstract] [Full Text] [Related]

  • 11. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging 18F-FDG PET/CT.
    Okuyucu K, Ince S, Alagoz E, Emer O, San H, Balkan E, Ayan A, Meric C, Haymana C, Acıkel C, Gunalp B, Karacalioglu AO, Arslan N.
    Hell J Nucl Med; 2016 Nov; 19(3):208-217. PubMed ID: 27824959
    [Abstract] [Full Text] [Related]

  • 12. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management.
    Schreinemakers JM, Vriens MR, Munoz-Perez N, Guerrero MA, Suh I, Rinkes IH, Gosnell J, Shen WT, Clark OH, Duh QY.
    World J Surg Oncol; 2012 Sep 17; 10():192. PubMed ID: 22985118
    [Abstract] [Full Text] [Related]

  • 13. Detection of residual lymph node metastases in high-risk papillary thyroid cancer patients receiving adjuvant I-131 therapy: the usefulness of F-18 FDG PET/CT.
    Kaneko K, Abe K, Baba S, Isoda T, Yabuuchi H, Sasaki M, Hatakenaka M, Honda H.
    Clin Nucl Med; 2010 Jan 17; 35(1):6-11. PubMed ID: 20026964
    [Abstract] [Full Text] [Related]

  • 14. Initial [18F]FDG PET/CT in high-risk DTC patients. A three-year follow-up.
    Ruhlmann M, Binse I, Bockisch A, Rosenbaum-Krumme SJ.
    Nuklearmedizin; 2016 Jun 28; 55(3):99-103. PubMed ID: 26830084
    [Abstract] [Full Text] [Related]

  • 15. Prognostic value of preoperative 18F-FDG PET/CT in papillary thyroid cancer patients with a high metastatic lymph node ratio: a multicenter retrospective cohort study.
    Kwon SY, Choi EK, Kong EJ, Chong A, Ha JM, Chun KA, Cho IH, Bom HS, Min JJ, Kim J, Song HC, O JH, Kim SH.
    Nucl Med Commun; 2017 May 28; 38(5):402-406. PubMed ID: 28306621
    [Abstract] [Full Text] [Related]

  • 16. Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients.
    Pace L, Klain M, Salvatore B, Nicolai E, Zampella E, Assante R, Pellegrino T, Storto G, Fonti R, Salvatore M.
    Clin Nucl Med; 2015 Feb 28; 40(2):111-5. PubMed ID: 25546215
    [Abstract] [Full Text] [Related]

  • 17. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, Tanabe H, Fukukura Y, Nakabeppu Y, Koriyama C.
    Radiology; 2013 Jun 28; 267(3):891-901. PubMed ID: 23468571
    [Abstract] [Full Text] [Related]

  • 18. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
    Liu FH, Kuo SF, Hsueh C, Chao TC, Lin JD.
    J Surg Oncol; 2015 Aug 28; 112(2):149-54. PubMed ID: 26175314
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with positive F-18 flurodeoxyglucose positron emission tomography before thyroidectomy in patients with papillary thyroid carcinoma.
    Kim BS, Kim SJ, Kim IJ, Pak K, Kim K.
    Thyroid; 2012 Jul 28; 22(7):725-9. PubMed ID: 22524470
    [Abstract] [Full Text] [Related]

  • 20. The Role of SPECT/CT Lymphoscintigraphy and Radioguided Sentinel Lymph Node Biopsy in Managing Papillary Thyroid Cancer.
    Cabrera RN, Chone CT, Zantut-Wittmann DE, Matos PS, Ferreira DM, Pereira PS, Ribeiro MP, Santos AO, Ramos CD, Crespo AN, Etchebehere EC.
    JAMA Otolaryngol Head Neck Surg; 2016 Sep 01; 142(9):834-41. PubMed ID: 27366869
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.